Growing J&J sales tempered by rising costs

23 January 2024
johnson-and-johnson-hq-big

US healthcare giant Johnson & Johnson (NYSE: JNJ) announced its fourth-quarter and annual financial results for 2023 on Tuesday.

The firm reported fourth-quarter reported sales growth of 7.3% to $21.4 billion, which was 2% higher than the consensus estimate of analysts, according to Leerink Partners.

The fourth-quarter adjusted earnings per share figure of $2.29 - compared to last year's $2.05 - was essentially in line with the consensus estimate of $2.28, and would have been greater had it not been for operating income being 7% below the expected amount.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical